Elevated FBXL6 expression in hepatocytes activates VRK2-transketolase-ROS-mTOR-mediated immune evasion and liver cancer metastasis in mice

참고문헌 (46)

1. De Toni, E. N., "Age independent survival benefit for patients with hepatocellular carcinoma(HCC)without metastases at diagnosis : a population-based study", Gut, 69, pp.168~176 (2020)[DOI]
2. Xu, I. M., "Transketolase counteracts oxidative stress to drive cancer development", Proc. Natl. Acad. Sci. USA, 113, pp.E725~E734 (2016)[DOI]
3. Llovet, J. M., "Sorafenib in advanced hepatocellular carcinoma", N. Engl. J. Med, 359, pp.378~390 (2008)[DOI]
4. Cheng, A. L., "Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma : a phase III randomised, doubleblind, placebo-controlled trial", The Lancet Oncology, 10, pp.25~34 (2009)[DOI]
5. Waidmann, O., "Recent developments with immunotherapy for hepatocellular carcinoma", Expert Opinion Biol. Therapy, 18, pp.905~910 (2018)[DOI]
6. Zhu, L., "Ubiquitinome profiling reveals the landscape of ubiquitination regulation in rice young panicles", Genomics Proteomics Bioinf, 18, pp.305~320 (2020)[DOI]
7. Gwon, Y., "Ubiquitination of G3BP1 mediates stress granule disassembly in a context-specific manner", Science, 372, pp.eabf6548~ (2021)[DOI]
8. Wang, G., "SETDB1-mediated methylation of Akt promotes its K63-linked ubiquitination and activation leading to tumorigenesis", Nat. Cell Biol, 21, pp.214~225 (2019)[DOI]
9. Schapira, M., "Targeted protein degradation: expanding the toolbox", Nat. Rev. Drug Discov, 18, pp.949~963 (2019)[DOI]
10. Wang, D., "E3 ubiquitin ligases in cancer and implications for therapies", Cancer Metastasis Rev, 36, pp.683~702 (2017)[DOI]
11. Yeh, C. H., "FBXW7: a critical tumor suppressor of human cancers", Mol. Cancer, 17, pp.115~ (2018)[DOI]
12. Mao, J. H., "FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression", Science, 321, pp.1499~1502 (2008)[DOI]
13. Cai, Z., "The Skp2 pathway : A critical target for cancer therapy", Seminars in Cancer Biol, 67, pp.16~33 (2020)[DOI]
14. Shi, W., "FBXL6 governs c-MYC to promote hepatocellular carcinoma through ubiquitination and stabilization of HSP90AA1", Cell Commun. Signal, 18, pp.100~ (2020)[DOI]
15. Schenk, G., "Properties and functions of the thiamin diphosphate dependent enzyme transketolase", Int. J. Biochem. Cell Biol, 30, pp.1297~1318 (1998)[DOI]
16. Yang, Z., "Inhibition of neddylation modification by MLN4924 sensitizes hepatocellular carcinoma cells to sorafenib", Oncol. Rep, 41, pp.3257~3269 (2019)[DOI]
17. Li, M., "The nuclear translocation of transketolase inhibits the farnesoid receptor expression by promoting the binding of HDAC3 to FXR promoter in hepatocellular carcinoma cell lines", Cell Death Dis, 11, pp.31~ (2020)[DOI]
18. Chen, H., "Overexpression of transketolase-like gene 1 is associated with cell proliferation in uterine cervix cancer", J. Exp. Clin. Cancer Res, 28, pp.43~ (2009)[DOI]
19. Uhlén, M., "Proteomics. Tissue-based map of the human proteome", Science, 347, pp.1260419~ (2015)[DOI]
20. Tseng, C. W., "Transketolase regulates the metabolic switch to control breast cancer cell metastasis via the α-ketoglutarate signaling pathway", Cancer Res, 78, pp.2799~2812 (2018)[DOI]
21. Yang, H., "MicroRNA-497 regulates cisplatin chemosensitivity of cervical cancer by targeting transketolase", Am. J. Cancer Res, 6, pp.2690~2699 (2016)
22. Qin, Z., "Transketolase(TKT)activity and nuclear localization promote hepatocellular carcinoma in a metabolic and a non-metabolic manner", J. Exp. Clin. Cancer Res, 38, pp.154~ (2019)[DOI]
23. Monsalve, D. M., "Human VRK2 modulates apoptosis by interaction with BclxL and regulation of BAX gene expression", Cell Death Dis, 4, pp.e513~ (2013)[DOI]
24. Hirata, N., "Functional characterization of lysosomal interaction of Akt with VRK2", Oncogene, 37, pp.5367~5386 (2018)[DOI]
25. Vázquez-Cedeira, M., "Human VRK2 (vaccinia-related kinase 2) modulates tumor cell invasion by hyperactivation of NFAT1 and expression of cyclooxygenase-2", J. Biol. Chem, 287, pp.42739~42750 (2012)[DOI]
26. Fernández, I. F., "VRK2 inhibits mitogen-activated protein kinase signaling and inversely correlates with ErbB2 in human breast cancer", Mol. Cellular Biol, pp.4687~4697 (2010)[DOI]
27. Chen, J., "VRK2 activates TNFα", NF-κB signaling by phosphorylating IKKβ in pancreatic cancer, 2022, pp.18, 1288~1302
28. Sanz-García, M., "Proteomics identification of nuclear Ran GTPase as an inhibitor of human VRK1 and VRK2 (vaccinia-related kinase) activities", Mol Cellular Proteomics, 7, pp.2199~2214 (2008)[DOI]
29. Xie, Z., "Exosome-delivered CD44v6", C1QBP complex drives pancreatic cancer liver metastasis by promoting fibrotic liver microenvironment, 2022, pp.71, 568~579
30. Zhang, B., "TSPAN15 interacts with BTRC to promote oesophageal squamous cell carcinoma metastasis via activating NF-κB signaling", Nat. Commun, 9, pp.1423~ (2018)[DOI]
31. Zhu, X., "TRIM21 suppresses CHK1 activation by preferentially targeting CLASPIN for K63-linked ubiquitination", Nucleic Acids Res, 50, pp.1517~1530 (2022)[DOI]
32. Mallette, F. A., "K48-linked ubiquitination and protein degradation regulate 53BP1 recruitment at DNA damage sites", Cell Res, 22, pp.1221~1223 (2012)[DOI]
33. Zhao, J., "TRIM26 positively regulates the inflammatory immune response through K11-linked ubiquitination of TAB1", Cell Death Differ, 28, pp.3077~3091 (2021)[DOI]
34. Swaney, D. L., "Global analysis of phosphorylation and ubiquitylation crosstalk in protein degradation", Nat. Methods, 10, pp.676~682 (2013)[DOI]
35. Saha, A., "Akt phosphorylation and regulation of transketolase is a nodal point for amino acid control of purine synthesis", Mol. Cell, 55, pp.264~276 (2014)[DOI]
36. Yin, Y., "The FBXW2-MSX2-SOX2 axis regulates stem cell property and drug resistance of cancer cells", Proc. Natl. Acad. Sci. USA, 116, pp.20528~20538 (2019)[DOI]
37. Yang, C., "TEOA promotes autophagic cell death via ROS-mediated inhibition of mTOR", p70S6k signaling pathway in pancreatic cancer cells, 2021, pp.9, 734818~
38. Liu, D., "Selenium and taurine combination is better than alone in protecting lipopolysaccharide-induced mammary inflammatory lesions via activating PI3K", Akt, Oxidative Med. Cellular Longevity, pp.2021, 2021[DOI]
39. Zhang, L., "Inhibition of transketolase improves the prognosis of colorectal cancer", Front. Med, 9, pp.837143~ (2022)[DOI]
40. Roukens, M. G., "Downregulation of vertebrate Tel (ETV6) and Drosophila Yan is facilitated by an evolutionarily conserved mechanism of F-box-mediated ubiquitination", Mol. Cellular Biol, 28, pp.4394~4406 (2008)[DOI]
41. Hill, M. A., "Kras and Tp53 mutations cause cholangiocyte-and hepatocytederived cholangiocarcinoma", Cancer Res, 78, pp.4445~4451 (2018)[DOI]
42. Wang, Z., "Nuclear Tkt promotes ischemic heart failure via the cleaved Parp1", Aif axis, 2022, pp.117, 18~
43. Zhu, H., "Vaccinia-related kinase 2 drives pancreatic cancer progression by protecting Plk1 from Chfr-mediated degradation", Oncogene, 40, pp.4663~4674 (2021)[DOI]
44. Chen, S., "Vaccinia-related kinase 2 blunts sorafenib’s efficacy against hepatocellular carcinoma by disturbing the apoptosis-autophagy balance", Oncogene, 40, pp.3378~3393 (2021)[DOI]
45. Lu, L. G., "PD-L1 blockade liberates intrinsic antitumourigenic properties of glycolytic macrophages in hepatocellular carcinoma", Gut, 71, pp.2551~2560 (2022)[DOI]
46. Guan, X., "Nanoparticle-enhanced radiotherapy synergizes with PD-L1blockade to limit post-surgical cancer recurrence and metastasis", Nat. Commun, 13, pp.2834~ (2022)[DOI]

관련 논문AI추천